Results 61 to 70 of about 92,066 (229)

Características das infecções em indivíduos portadores de neoplasias hematológicas internados no Hospital Universitário Professor Polydoro Ernani de São Thiago [PDF]

, 2014
Dissertação (mestrado profissional) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação Multidisciplinar em Saúde, Florianópolis, 2014.As neoplasias malignas do sistema hematopoiético atingem células ...
Almeida, Adriana Brejinski de
core  

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia [PDF]

Journal of Microbiology and Infectious Diseases, 2016
Objective: Pediatric cancer patients with prolonged febrile neutropenia have increased risk for severe, recurrent or new bacterial and fungal infection.
Muhammad Matloob Alam
doaj   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim

, 2019
Aim: Neutropenia is a common side effect of myelosuppressive chemotherapy. Administration of granulocyte colony-stimulating factor is being used for neutropenia prophylaxis, but there are patients who develop neutropenia or febrile neutropenia despite ...
곽혜선
core   +1 more source

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update

Advances in Hematology, 2014
Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival.
Paola Villafuerte-Gutierrez, Lucia Villalon, Juan E. Losa, Cesar Henriquez-Camacho   +3 more
doaj   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Uso de factores de crescimento de granulócitos: recomendações da Sociedade Portuguesa de Hematologia.

Acta Médica Portuguesa, 2008
The administration of cytotoxic chemotherapy may be complicated by the emergence of neutropenia and febrile neutropenia, frequently determining hospital admission and intravenous treatment with broad spectrum antibiotics.
João Forjaz de Lacerda, Fernando Leal da Costa, Ana Marques Pereira, Fernando Príncipe, Adriana Teixeira, António Parreira   +5 more
doaj   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Testing for Bacteria and Fungi in Cells and Ancillary Reagents—Probe‐Based Quantitative PCR Assays

Cell Proliferation, EarlyView.
This document specifies the technical elements for bacteria and fungi detection by PCR assay which enables rapid, broad‐spectrum detection of bacteria and fungi with high sensitivity. Qualitative judgement is based on LOD. Key detection points include efficient nucleic acid extraction, broad‐spectrum primer‐probe design, high amplification efficiency ...
Jiani Cao, Ranran Xu, Boqiang Fu, Jie Hao, Lei Wang, Aijin Ma, Qiang Wei, Hongling Zhao, Chunming Rao, Qiyuan Li, Tao Na, Shijun Hu, Lihua Zhou, Weiqi Zhang, Qubo Chen, Siming Sun, Zengshu Liu, Shuaishuai Niu, Tingting Zhang, Yuanyuan Zhang, Yidi Gan, Shuyan Wang, Glyn N. Stacey, Jun Wei, Tongbiao Zhao, Yu Alex Zhang   +25 more
wiley   +1 more source